OpportunityTitle: Limited Competition: Revisions to Add Phase 2 Clinical Trials Program to Experimental Therapeutics Clinical Trials Network (ETCTN)(UM1)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following: Only current ETCTN UM1 awardees may submit revision applications invited by this FOA (including Canadian recipients of the ETCTN award). See full announcement for full details.
Description: The purpose of this Funding Opportunity Announcement (FOA) is to enhance the NCI-supported early development of experimental cancer therapeutics by merging the Phase 2 clinical trials program with the Experimental Therapeutics Clinical Trials Network (ETCTN, funded through RFA-CA-13-006) that is currently focused on Phase 1 clinical trials. The FOA invites revision applications from ETCTN UM1 awardees to expand the scope of activities by adding capabilities to conduct Phase 2 clinical trials. The goal is to integrate Phase 2 infrastructure and expertise to create a unified network for an efficient and comprehensive conduct of early clinical trials. This integration of the Phase 2 capabilities into the new ETCTN structure will allow for more seamless advancement of experimental agents through early stages of development. Ultimately, the expected increased efficiency of clinical trial management is expected to accelerate the delivery of new cancer therapies to the public.
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;FBOWebmaster@OD.NIH.GOV&lt;br/&gt;